However, overall, GBM patients have responded poorly to current immunotherapies 16, largely due to the local and systemic immunosuppression in GBM patients 17, tumor heterogeneity and instability which is associated with the failure of a phase III clinical trial of a epidermal growth factor receptor variant III (EGFRvIII) vaccines 16,18, central immune tolerance against conventional tumor-associated vaccines, low tumor mutation burdens, and poor immunogenicity of the majority of tumor neoepitopes 19-21. The gene discussed is EGFR; the disease is neoplasm.